Abstract 72P
Background
Group 3 Medulloblastoma (MB) is a subgroup of MB with poor prognosis and high chances of recurrence. The highly aggressive nature of this paediatric brain tumor necessitates targeted therapeutic approaches to improve patient outcomes. Phosphoenolpyruvate carboxykinase plays a crucial role in gluconeogenesis by catalyzing the conversion of oxaloacetate to phosphoenolpyruvate. PCK2 is the mitochondrial counterpart of this enzyme, helping in replenishment of various metabolic intermediates and hence acting as a pivotal protein between pyruvate metabolism, TCA cycle and gluconeogenesis. Recent proteomic studies on Medulloblastoma (MB) suggest extensive metabolic rewiring in Group 3 MB.
Methods
Analysis of publicly available omics data on Medulloblastoma was performed to identify the expression levels of proteins related to key metabolic pathways like Krebs cycle, pyruvate metabolism and glucose metabolism including PCK2. Key proteins belonging to these pathways were analysed in FFPE tissues from MB patients and compared with other subgroups using multiple reaction monitoring. PCK2 was knocked down in Group 3 cell lines using shRNA and evaluated for effects on proliferation and survival using culture based in vitro assays. High resolution label free proteomic analysis was performed to ascertain the effects of PCK2 knockdown.
Results
Data mining and repository data analysis found dysregulation of key proteins and metabolites. Key proteins involved in energy metabolism including PCK2 showed upregulation even at the transcriptomic level. Proteomic analysis on few FFPE samples could validate these findings. shRNA based PCK2 knockdown resulted in lowering the proliferation rates of Group 3 cells and significant changes in their proteomes.
Conclusions
The overexpression of PCK2 is involved in the aggressiveness of Group 3 MB and can be a possible target for this subset of medulloblastoma patients.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
IIT Bombay.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
10P - An adapted CGP-based model to interpret POLE mutations in endometrial cancer
Presenter: Rita Trozzi
Session: Cocktail & Poster Display session
Resources:
Abstract
11P - Reconstructing tumour evolution of single cells using both somatic mutations and copy-number alterations
Presenter: Rija Zaidi
Session: Cocktail & Poster Display session
Resources:
Abstract
12P - Swiss-PO: Molecular modelling for precision oncology
Presenter: Fanny Krebs
Session: Cocktail & Poster Display session
Resources:
Abstract
13P - A novel algorithm for predicting variant detectability in oncogenomic analysis
Presenter: Alper Akkuş
Session: Cocktail & Poster Display session
Resources:
Abstract
14P - expHRD: An algorithm for the transcriptome-based estimation of homologous recombination deficiency score
Presenter: Jin-Ku Lee
Session: Cocktail & Poster Display session
Resources:
Abstract
15P - ClinBioNGS: An integrated clinical bioinformatics pipeline for the analysis of somatic NGS cancer panels
Presenter: Xavier Sole
Session: Cocktail & Poster Display session
Resources:
Abstract
16P - Investigation of c-MYC role in DNA-PK-mediated activation of STING pathway in SCLC
Presenter: Caterina de Rosa
Session: Cocktail & Poster Display session
Resources:
Abstract
17P - NRF2 activation promotes HER2-targeted tolerance and resistance in oesophageal adenocarcinoma through metabolic reprogramming to glutathione
Presenter: Wei Zhang
Session: Cocktail & Poster Display session
Resources:
Abstract
18P - AURKB inhibition radiosensitises NSCLC by altering mitotic fate
Presenter: Kathryn Egerton
Session: Cocktail & Poster Display session
Resources:
Abstract
19P - Stratified control study on neuroendocrine differentiation and potential clinical markers in patients with limited-stage small-cell lung cancer
Presenter: Li Liu
Session: Cocktail & Poster Display session
Resources:
Abstract